This study compares two dose strengths of a new epilepsy medicine to placebo for treatment of refractory focal onset epilepsy as measured by the change in 28-day average seizure frequency.
Thank you for your interest, but this study is recruiting by invitation only.
United States (Nationwide)
Angela Wabulya
Neurology
Clinical or Medical
Interventional
Brain, Head, Nervous System
24-0840
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
